Antigen-pulsed dendritic cell vaccine combined with hyperthermia in treatment of advanced non-small cell lung cancer
- VernacularTitle:肿瘤抗原致敏树突状细胞疫苗联合热疗治疗晚期非小细胞肺癌的临床观察
- Author:
Liming ZHU
;
Yiping ZHANG
;
Xinmin YU
;
Qinghua DENG
;
Zhibing WU
;
Shenglin MA
- Publication Type:Journal Article
- Keywords:
dendritic cell;
vaccine;
hyperthermia;
non-small cell lung cancer;
immunotherapy
- From:
Chinese Journal of Cancer Biotherapy
1994;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and clinical efficacy of antigen-pulsed dendritic cell (APDC) vaccine combined hyperthermia in treating advanced non-small cell lung cancer (NSCLC). Methods: Fourteen patients with advanced NSCLC were enrolled in this study. All patients met the selecting standard and signed informed consent. Human dendritic cells were derived from peripheral blood monocytes by co-culturing them with granulocyte macrophage-colony stimulating factor and interleukin-4. DCs vaccine was prepared from antigen pulsed immature dendritic cells in vitro. The vaccine therapy was given once every week following local hyperthermia by NRL-001 Double RF Tumor Hyperthermia system (39.5 ℃-41 ℃ for 60-120 min). Every three-week was defined as a treatment cycle. Results: All patients received 16 cycles of combined treatment. The main adverse effect included fever, chill, myalgia, transient fatigue, itching, chest distress, local rashes, and blister. Seven of 14 patients had stable condition after treatment and another seven had a progressing condition, with a clinical beneficial rate of 50%. Median time to progress was 2.7 months in the patients and the overall survival period was 2.5 to 29.3 months, with the median survival time being 4.9 months; the one year survival rate was 21.4% in our group. Conclusion: The results suggest that combination of APDC vaccine therapy and local hyperthermia is well tolerated by NSCLC patients and is clinically beneficial to the patients; the clinical value of this therapy needs to be further studied.
